SCHEDULE: Udi Gilboa Reports 21.1% Stake in Nasus Pharma
Beneficial Ownership Disclosure
Udi Gilboa has reported beneficial ownership of 21.1% of Nasus Pharma Ltd.'s ordinary shares as of September 30, 2025.
Summary
- Udi Gilboa, a citizen of Israel, has filed a Schedule 13G disclosing beneficial ownership in Nasus Pharma Ltd.
- As of September 30, 2025, Udi Gilboa beneficially owns 1,901,311 ordinary shares of Nasus Pharma Ltd.
- This ownership represents 21.1% of the issuer's ordinary shares outstanding.
- The percentage is based on 9,014,105 ordinary shares that Nasus Pharma Ltd. advised were issued and outstanding as of September 30, 2025.
- Udi Gilboa holds sole voting power and sole dispositive power over all 1,901,311 beneficially owned shares.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would significantly sway sentiment positively or negatively beyond the implications of a large individual stake.
Positives
- A significant beneficial ownership stake by an individual, potentially an insider, can signal strong confidence in the company's future prospects.
Negatives
- The filing itself does not contain inherently negative information, as it is a disclosure of ownership.
Risks
- A concentrated ownership stake of 21.1% by a single individual could lead to significant influence over corporate decisions, potentially impacting minority shareholders.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
This filing is a standard regulatory disclosure of significant beneficial ownership and does not provide specific industry context or competitive analysis.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Ownership Concentration | Udi Gilboa's 21.1% beneficial ownership stake grants significant voting power, which could influence corporate governance decisions and potentially impact the balance of power among shareholders. | 09/30/2025 | This level of ownership provides substantial influence, which could be a factor in strategic decisions, board appointments, and other corporate actions. |
Stakeholder Impact
- Shareholders: The significant stake held by Udi Gilboa means a substantial portion of voting power is concentrated, which could affect the influence of other shareholders in corporate matters.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of the event which required the filing of this statement, reflecting the beneficial ownership. |
| 11/10/2025 | Date the Schedule 13G statement was signed and filed by Udi Gilboa. |
Keywords
Nasus Pharma Ltd., Udi Gilboa, Beneficial Ownership, Schedule 13G, Ordinary Shares, Equity Stake, Shareholder, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.